This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Mundipharma International Limited

Drug Names(s): forodesine HCL, BCX-1777

Description: Fodosine is a PNP inhibitor of human lymphocyte proliferation.

Deal Structure: BioCryst, Albert Einstein College of Medicine, and Industrial Research
In June 2000, BioCryst licensed a series of PNP inhibitors (includng forodesine) from the Albert Einstein College of Medicine (AECOM) in New York and Industrial Research Limited (IRL) of New Zealand. BioCryst has worldwide exclusive rights to develop and ultimately distribute this compound and has agreed to pay certain milestone payments for future development of the drug, certain royalties on sales of any resulting product, and to share in future payments received from other third-party partners, if any. In addition, it has agreed to pay an annual license fee that is non-refundable, but is creditable against actual royalties and other payments due to AECOM and IRL.

BioCryst and Mundipharma
In February 2006, BioCryst Pharmaceuticals and Mundipharma International Holdings Limited announced that they entered into an exclusive license agreement to develop and commercialize Fodosine in...See full deal structure in Biomedtracker

Partners: BioCryst Pharmaceuticals, Inc.

Fodosine News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug